Metastatic Breast Cancer
Conditions
Keywords
metastatic breast cancer, amrubicin
Brief summary
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
Interventions
DRUGAmrubicin
Sponsors
Celgene Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological diagnosis of breast cancer. * Metastatic or recurrent disease, either HER2+ (FISH+ or 3+ IHC) or HER2-. * Maximal dose of prior adjuvant anthracycline: 300 mg/meters squared doxorubicin or equivalent. Relapse greater than one year after trastuzumab adjuvantly; two years following adjuvant anthracycline therapy (without trastuzumab). * One prior chemotherapy for metastatic breast cancer allowed (may include trastuzumab for HER2+ patients), but no prior Doxil, adriamycin or epirubicin for metastatic breast cancer. * At least 18 years of age. * ECOG Performance Status of 0, 1, or 2. * Adequate organ function including the following: * Adequate bone marrow reserve. * Cardiac: Left ventricular ejection fraction (LVEF) greater than or equal to 55% by MUGA. * Negative serum pregnancy test at the time of enrollment for women of child-bearing potential. * Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.
Exclusion criteria
* Pregnant or nursing women. * Concurrent anticancer therapy. * Participation in any investigational drug study within 28 days prior to study entry. * Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, uncontrolled hypertension, coronary artery disease, congestive heart failure, severe arrhythmia) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study. * Symptomatic central nervous system metastases. Patients with asymptomatic brain metastases are allowed. The patient must be stable after radiotherapy for greater than or equal to 2 weeks and off corticosteroids for greater than or equal to 1 week. * History of interstitial lung disease or pulmonary fibrosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardiac toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks) | — |
| Duration of overall response | — |
| Time to tumor progression | — |
| Progression free survival | — |
| Toxicity profile | — |
Countries
United States
Outcome results
None listed